Folio · SPXSet Report · Digest
v0.7.0 STABLE · 2026-11-11 · r4

2026-W46 · Nov 9–Nov 15 · Company · Profile · published

Index >>> Company >>> Profile

Medtronic plc (MDT) — XLV Health Care · S&P 500 Profile |美敦力公司介紹

health-careS&P500xlvxlv-top-25
SPXSet Studio
IN-HOUSE RESEARCH · 站內獨立研究

Medtronic plc (MDT) — Business, History & S&P 500 Profile |美敦力公司介紹

Medtronic company profile · cardiovascular, neuroscience & medical surgical devices · history · financial snapshot · S&P 500 rank #95 · 美敦力公司業務歷史財務與標普500地位

中文版 ↓

PROFILE
Market data as of Oct 29, 2026 (frozen benchmark)
Financials: FY2026 (ended Apr 24, 2026)
MARKET CAP
$124.22B
Oct 29, 2026 (frozen benchmark)
S&P 500 WEIGHT
0.18%
Rank #95 · Oct 29, 2026 (Slickcharts)
FY2026 NET SALES
$36.36B
+8.4% YoY · highest growth in 10 years
FY2026 NET INCOME
$4.80B
Diluted EPS $3.73

SNAPSHOT

TickerMDT (NYSE)
CompanyMedtronic plc
GICS sector / industryHealth Care (XLV) / Health Care Equipment
S&P 500 rank (by weight)#95 · 0.18% (Oct 29, 2026)
Sector rank (by market cap)#15 in Health Care (Oct 29, 2026)
HeadquartersGalway, Ireland
Founded1949, in Minneapolis, Minnesota
CEOGeoff Martha (chairman and CEO)
Employees95,000+ (FY2026)
Market cap$124.22B (Oct 29, 2026) · price $97.11
SEC filingsEDGAR — CIK 0001613103

WHAT IT DOES

Medtronic is the world’s largest pure-play medical device company, selling device-based therapies to hospitals and physicians in more than 150 countries. FY2026 net sales were $36.36B, up 8.4% as reported and 5.8% organically — the highest annual growth in a decade — on a fiscal year ended Apr 24, 2026.

Cardiovascular is the largest portfolio at $13.98B, led by cardiac rhythm and heart failure devices and by pulsed-field ablation (PFA) for atrial fibrillation, where cardiac ablation revenue surged 78% in Q4 FY2026. Neuroscience ($10.30B) covers cranial and spinal products, specialty therapies and neuromodulation; Medical Surgical ($8.80B) covers surgical and endoscopy products and acute care and monitoring.

The strategic story is focus: Medtronic separated Diabetes (FY2026 sales $3.11B) via the MiniMed IPO in March 2026, leaving three reportable portfolios, and is betting that PFA, structural heart and neuromodulation product cycles can sustain mid-single-digit organic growth against procedure-volume and pricing headwinds.

BUSINESS SEGMENTS — FY2026 NET SALES BY PORTFOLIO

PortfolioRevenueShareYoY
Cardiovascular$13.98B38.4%Not available
Neuroscience$10.30B28.3%Not available
Medical Surgical$8.80B24.2%Not available
Diabetes$3.11B8.6%Not available
Other$0.17B0.5%Not available
Total net sales$36.36B100%+8.4%
Source: Medtronic FY2026 Form 10-K (fiscal year ended Apr 24, 2026, filed Jun 18, 2026) and FY2026 results release. Diabetes stopped being a reportable segment in Q4 FY2026 after the MiniMed IPO; it is shown separately here so the rows sum to total net sales of $36.36B. Segment YoY is Not available on a like-for-like reported basis in the verified sources used here.

HISTORY

1949Earl Bakken and Palmer Hermundslie found Medtronic in Minneapolis as a medical equipment repair shop
1957Builds the first battery-powered wearable pacemaker after a power failure kills a young patient
1960Ships the first implantable pacemaker, creating the cardiac rhythm industry
2001Acquires MiniMed for $3.28B, entering diabetes management
2014Announces the Covidien acquisition, the largest in Medtronic history
2015Closes Covidien and moves its legal headquarters to Ireland
2023PulseSelect pulsed-field ablation system wins US FDA approval
2024Sphere-9 dual-energy catheter with Affera mapping wins US FDA approval
2025Announces the separation of the Diabetes business as a standalone company
2026MiniMed Group completes its initial public offering on Mar 9, 2026

COMPETITIVE POSITION

  • PFA leadership — PulseSelect and Sphere-9/Affera put Medtronic at the front of the electrophysiology shift from thermal to pulsed-field ablation.
  • Breadth — no rival matches the combined cardiovascular, neuroscience and surgical portfolio, giving cross-selling and hospital-contract leverage.
  • Scale manufacturing and R&D — a $36.36B sales base funds device trials and regulatory work smaller rivals cannot match.
  • MiniMed separation — a standalone diabetes company can invest and partner on its own terms, while Medtronic sharpens its device focus.
  • Competition — Abbott, Boston Scientific and Johnson & Johnson (MedTech) contest every major portfolio; Stryker and Zimmer Biomet contest spine and surgical.

FINANCIAL SNAPSHOT — FY2026

Net sales$36.36B (+8.4% YoY)
Gross profit$23.75B
Operating income$6.47B
Net income$4.80B (+3.0% YoY)
Diluted EPS$3.73 (GAAP)
Free cash flow$5.43B
Total assets$93.03B (Apr 24, 2026)
Research and developmentNot available
Source: Medtronic FY2026 Form 10-K consolidated statements (filed Jun 18, 2026). Operating income of $6.47B is on the 17.8% operating-margin basis reported for FY2026; a higher operating-income figure in some databases includes other items and is not used here.

KEY RISKS

  • Procedure and pricing pressure — hospital budgets, payer negotiations and device price erosion can slow even a strong product cycle.
  • Regulatory and recall risk — FDA clearance timelines, safety findings and recalls hit device makers directly and publicly.
  • Competition in PFA — Boston Scientific and Johnson & Johnson are investing heavily in ablation; share gains in FY2026 are not guaranteed to hold.
  • Tariffs and supply chain — management flagged a tariff drag for FY2027; components and sterilisation capacity remain pinch points.
  • Separation execution — MiniMed disentanglement, stranded costs and transition agreements can distract from the core portfolios.

WHY IT MATTERS FOR THE S&P 500

Medtronic is the S&P 500’s medical-device bellwether: at a 0.18% index weight and the #15 market cap in Health Care, it is the index’s main exposure to hospital procedure volumes and device innovation rather than to drugs.

Its PFA ramp is the sector’s most watched product cycle — ablation growth, procedure volumes and hospital capital spending show up in Medtronic results before they show up in sector aggregates.

SOURCES & METHODOLOGY

Market dataSlickcharts S&P 500 by weight (rank, weight, price — Oct 29, 2026 crawl)
FinancialsMedtronic FY2026 Form 10-K (SEC EDGAR, filed Jun 18, 2026) and FY2026 results release
Sector classificationGICS (Health Care Equipment) via the List of S&P 500 companies (Wikipedia)
Library dataSPXSet logo library, compiled from company official websites, filings, or Wikipedia; as company logos are dynamic corporate information, no 100% guarantee is made for the graphics. SPXSet chart library, monthly bars, compiled from Yahoo public information.

Price Chart — 10-Year Monthly Candles

Medtronic

Source: Yahoo Finance monthly bars, split-adjusted · Data as of Sep 30, 2026 (last closed month) · SPXSet.com

FINANCIALS

繁體中文版

公司快照

代碼MDT(NYSE)
公司Medtronic plc
GICS 板塊/行業醫療保健(XLV)/醫療保健設備
標普500排名(按權重)#95 · 0.18%(2026 年 10 月 29 日)
板塊內排名(按市值)醫療保健第 #15(2026 年 10 月 29 日)
總部愛爾蘭戈爾韋
成立1949 年,於明尼蘇達州明尼阿波利斯
行政總裁Geoff Martha(主席兼行政總裁)
員工95,000+(FY2026)
市值$124.22B(2026 年 10 月 29 日)· 價格 $97.11
SEC 申報EDGAR — CIK 0001613103

業務概覽

美敦力是全球最大的純醫療器械公司,向 150 多個國家的醫院與醫生銷售器械療法。FY2026 淨銷售額為 $36.36B,按申報增長 8.4%、按有機口徑增長 5.8%,為十年來最高年度增速;財政年度截至 2026 年 4 月 24 日。

心血管為最大組合($13.98B),以心律與心衰器械及房顫脈衝電場消融(PFA)為主,其中心臟消融收入在 FY2026 第四季激增 78%。神經科學($10.30B)涵蓋顱腦與脊柱產品、專科療法與神經調控;醫療外科($8.80B)涵蓋外科與內窺鏡產品及急症護理與監護。

戰略主線是聚焦:美敦力於 2026 年 3 月通過 MiniMed 上市分拆糖尿病業務(FY2026 銷售額 $3.11B),剩下三個報告組合,並押注 PFA、結構性心臟與神經調控產品週期能抵禦手術量與定價壓力,維持中個位數有機增長。

業務板塊 — FY2026 淨銷售額(按組合)

組合收入佔比同比
心血管$13.98B38.4%Not available
神經科學$10.30B28.3%Not available
醫療外科$8.80B24.2%Not available
糖尿病$3.11B8.6%Not available
其他$0.17B0.5%Not available
淨銷售額總計$36.36B100%+8.4%
來源:美敦力 FY2026 Form 10-K(財政年度截至 2026 年 4 月 24 日,2026 年 6 月 18 日申報)及 FY2026 業績公告。糖尿病業務在 FY2026 第四季 MiniMed 上市後不再列為報告板塊;本表將其單列,使各行合計為淨銷售額 $36.36B。板塊同比按可比申報口徑在本稿核實來源中為 Not available。

歷史沿革

1949Earl Bakken 與 Palmer Hermundslie 在明尼阿波利斯創立美敦力,起初為醫療設備維修店
1957一名年輕病人因停電身亡後,研製首台電池供電可穿戴起搏器
1960推出首台植入式起搏器,開創心律管理行業
2001以 $3.28B 收購 MiniMed,進入糖尿病管理領域
2014宣布收購 Covidien,為美敦力史上最大交易
2015完成收購 Covidien,法定總部遷至愛爾蘭
2023PulseSelect 脈衝電場消融系統獲美國 FDA 批准
2024Sphere-9 雙能量導管連 Affera 標測系統獲美國 FDA 批准
2025宣布將糖尿病業務分拆為獨立公司
2026MiniMed Group 於 2026 年 3 月 9 日完成首次公開發售

競爭地位

  • PFA 領導地位——PulseSelect 與 Sphere-9/Affera 使美敦力走在電生理由熱消融轉向脈衝電場消融的前列。
  • 廣度——心血管、神經科學與外科組合的合計廣度無對手能及,帶來交叉銷售與醫院合約議價力。
  • 製造與研發規模——$36.36B 的銷售基礎,資助小型對手無法負擔的器械試驗與監管工作。
  • MiniMed 分拆——獨立糖尿病公司可按自身條件投資與合作,美敦力則更聚焦器械業務。
  • 競爭——雅培、波士頓科學與強生(醫療科技)爭奪每個主要組合;史賽克與捷邁邦美爭奪脊柱與外科市場。

財務快照 — FY2026

淨銷售額$36.36B(同比 +8.4%)
毛利$23.75B
營業利潤$6.47B
淨利潤$4.80B(同比 +3.0%)
攤薄每股盈利$3.73(GAAP)
自由現金流$5.43B
總資產$93.03B(2026 年 4 月 24 日)
研發支出Not available
來源:美敦力 FY2026 Form 10-K 合併報表(2026 年 6 月 18 日申報)。營業利潤 $6.47B 按 FY2026 申報的 17.8% 營業利潤率口徑;部分數據庫較高的營業利潤數字含其他項目,本稿不採用。

主要風險

  • 手術量與定價壓力——醫院預算、支付方談判與器械價格侵蝕,即使產品週期強勁亦可能放緩。
  • 監管與召回風險——FDA 審批時間、安全發現與召回對器械廠商有直接而公開的衝擊。
  • PFA 競爭——波士頓科學與強生大力投資消融領域;FY2026 的份額增長未必能守住。
  • 關稅與供應鏈——管理層已提示 FY2027 的關稅拖累;零部件與滅菌產能仍是瓶頸。
  • 分拆執行——MiniMed 切割、遺留成本與過渡協議可能分散核心組合的注意力。

對標普500的重要性

美敦力是標普500中的醫療器械風向標:指數權重 0.18%、醫療保健板塊市值第 #15,是指數對醫院手術量與器械創新而非藥品的主要敞口。

其 PFA 爬坡是行業最受關注的產品週期——消融增長、手術量與醫院資本開支,往往先在美敦力業績中出現,再反映到行業總量。

來源與方法

市場數據Slickcharts 標普500權重榜(排名、權重、價格——2026 年 10 月 29 日抓取)
財務美敦力 FY2026 Form 10-K(SEC EDGAR,2026 年 6 月 18 日申報)及 FY2026 業績公告
板塊分類GICS(醫療保健設備),據 S&P 500 公司清單(Wikipedia)
圖庫數據SPXSet logo 庫,整理自企業官方網站、文件或維基百科;由於是企業自身動態資訊,不對圖形做百分百保證。SPXSet 圖表庫月線,整理自 Yahoo 公開資訊。

10年股價K線圖(月K)

Medtronic

來源:Yahoo Finance 月 K(經拆股調整)· 數據截至 2026 年 9 月 30 日(最後已收月份) · SPXSet.com

財報

SPXSet Studio

SPXSet in-house research — market structure, options and volatility. Not investment advice.
SPXSet 站內獨立研究,聚焦 SPX 市場結構、期權與波動率;內容不構成投資建議。

SPXSet · Company Library · MDT
Data as of Oct 29, 2026 · Financials FY2026 (10-K) · Market data Oct 2026
Previous · Prologis, Inc. (PLD) — XLRE Real Estate · S&P 500 Profile |普洛斯公司介紹Next · Bristol-Myers Squibb Company (BMY) — XLV Health Care · S&P 500 Profile |百時美施貴寶公司介紹

Entered 2026-10-30 04:31 · updated 2026-11-14 23:49 · rev 7